For the quarter ending 2026-03-31, NUVB made $83,228K in revenue. $3,907K in net income. Net profit margin of 4.69%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 83,228 | 41,865 | 13,120 | 4,833 |
| Cost of revenue | - | - | 3,349 | 2,576 |
| Cost of sales | 375 | 214* | - | - |
| Gross profit (deficit) | - | - | 9,771 | 2,257 |
| Cost of collaboration and license agreements revenue | 5,616 | 9,084* | - | - |
| Research and development | 35,047 | 34,297 | 28,846 | 27,362 |
| Acquired in-process research and development | - | 0* | 0 | 0 |
| Selling, general and administrative | 38,309 | 40,326 | 37,359 | 38,484 |
| Total costs and expenses | 79,347 | 83,921 | 66,205 | 65,846 |
| Income (loss) from operations | 3,881 | -34,037 | -56,434 | -63,589 |
| Interest income | 5,108 | 5,296 | 6,033 | 4,780 |
| Interest expense | 6,708 | 6,673 | 6,534 | 421 |
| Net gain on disposal of fixed assets | - | 12* | 4 | -34 |
| Investment advisory fees | 195 | 166 | 171 | 182 |
| Change in fair value of warrant liability | -2,865 | 1,127 | -612 | -454 |
| Realized gain on marketable securities | 8 | 3 | 0 | -1 |
| Other income (expense) | - | 100* | - | - |
| Other income | 438 | - | 698 | -14 |
| Total other income, net | 1,516 | -2,555 | 642 | 4,582 |
| Income (loss) before income taxes | 5,397 | -36,592 | -55,792 | -59,007 |
| Provision for income taxes | 0 | 0 | 0 | 0 |
| Net income (loss) | 5,397 | -36,592 | -55,792 | -59,007 |
| Currency translation adjustment | 268 | 1,007 | 313 | 646 |
| Change in unrealized loss on available-for-sale securities | -1,222 | 958 | 501 | -225 |
| Comprehensive income (loss) | 3,907 | -36,641 | -55,604 | -59,878 |
| Basic EPS | 0.02 | -106.387 | -0.16 | -0.17 |
| Diluted EPS | 0.01 | -106.387 | -0.16 | -0.17 |
| Basic Average Shares | 347,332 | 344,413 | 342,393 | 340,746 |
| Diluted Average Shares | 377,521 | 344,413 | 342,393 | 340,746 |
Nuvation Bio Inc. (NUVB)
Nuvation Bio Inc. (NUVB)